Targeting the RB-pathway in cancer therapy

Erik S. Knudsen, Jean Y J Wang

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

The RB-pathway, consisting of inhibitors and activators of cyclin-dependent kinases, the retinoblastoma tumor suppressor (RB), and the E2F-family of transcription factors, plays critical roles in the regulation of cell cycle progression and cell death. Components of this pathway, particularly p16Ink4a, cyclin D1, and RB, are frequently altered in sporadic human cancers to promote deregulated cellular proliferation. The consistent disruption of the RB-pathway in human cancers raises the possibility of exploiting tumor-specific RB-pathway defects to improve the efficacy of current therapies and to develop new therapeutic strategies. This article discusses how the RB-pathway status impacts the cellular responses to cytotoxic, cytostatic, and hormone therapies, and how the components of the RB-pathway may be directly targeted to treat cancer.

Original languageEnglish (US)
Pages (from-to)1094-1099
Number of pages6
JournalClinical Cancer Research
Volume16
Issue number4
DOIs
StatePublished - Feb 15 2010

Fingerprint

Neoplasms
E2F Transcription Factors
Therapeutics
Cyclin-Dependent Kinases
Retinoblastoma
Cyclin D1
Cytostatic Agents
Cell Cycle
Cell Death
Cell Proliferation
Hormones

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Targeting the RB-pathway in cancer therapy. / Knudsen, Erik S.; Wang, Jean Y J.

In: Clinical Cancer Research, Vol. 16, No. 4, 15.02.2010, p. 1094-1099.

Research output: Contribution to journalArticle

Knudsen, Erik S. ; Wang, Jean Y J. / Targeting the RB-pathway in cancer therapy. In: Clinical Cancer Research. 2010 ; Vol. 16, No. 4. pp. 1094-1099.
@article{c3a57e0b8b5e4fd0b6b3b54771bab0e4,
title = "Targeting the RB-pathway in cancer therapy",
abstract = "The RB-pathway, consisting of inhibitors and activators of cyclin-dependent kinases, the retinoblastoma tumor suppressor (RB), and the E2F-family of transcription factors, plays critical roles in the regulation of cell cycle progression and cell death. Components of this pathway, particularly p16Ink4a, cyclin D1, and RB, are frequently altered in sporadic human cancers to promote deregulated cellular proliferation. The consistent disruption of the RB-pathway in human cancers raises the possibility of exploiting tumor-specific RB-pathway defects to improve the efficacy of current therapies and to develop new therapeutic strategies. This article discusses how the RB-pathway status impacts the cellular responses to cytotoxic, cytostatic, and hormone therapies, and how the components of the RB-pathway may be directly targeted to treat cancer.",
author = "Knudsen, {Erik S.} and Wang, {Jean Y J}",
year = "2010",
month = "2",
day = "15",
doi = "10.1158/1078-0432.CCR-09-0787",
language = "English (US)",
volume = "16",
pages = "1094--1099",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Targeting the RB-pathway in cancer therapy

AU - Knudsen, Erik S.

AU - Wang, Jean Y J

PY - 2010/2/15

Y1 - 2010/2/15

N2 - The RB-pathway, consisting of inhibitors and activators of cyclin-dependent kinases, the retinoblastoma tumor suppressor (RB), and the E2F-family of transcription factors, plays critical roles in the regulation of cell cycle progression and cell death. Components of this pathway, particularly p16Ink4a, cyclin D1, and RB, are frequently altered in sporadic human cancers to promote deregulated cellular proliferation. The consistent disruption of the RB-pathway in human cancers raises the possibility of exploiting tumor-specific RB-pathway defects to improve the efficacy of current therapies and to develop new therapeutic strategies. This article discusses how the RB-pathway status impacts the cellular responses to cytotoxic, cytostatic, and hormone therapies, and how the components of the RB-pathway may be directly targeted to treat cancer.

AB - The RB-pathway, consisting of inhibitors and activators of cyclin-dependent kinases, the retinoblastoma tumor suppressor (RB), and the E2F-family of transcription factors, plays critical roles in the regulation of cell cycle progression and cell death. Components of this pathway, particularly p16Ink4a, cyclin D1, and RB, are frequently altered in sporadic human cancers to promote deregulated cellular proliferation. The consistent disruption of the RB-pathway in human cancers raises the possibility of exploiting tumor-specific RB-pathway defects to improve the efficacy of current therapies and to develop new therapeutic strategies. This article discusses how the RB-pathway status impacts the cellular responses to cytotoxic, cytostatic, and hormone therapies, and how the components of the RB-pathway may be directly targeted to treat cancer.

UR - http://www.scopus.com/inward/record.url?scp=76749104377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76749104377&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-09-0787

DO - 10.1158/1078-0432.CCR-09-0787

M3 - Article

C2 - 20145169

AN - SCOPUS:76749104377

VL - 16

SP - 1094

EP - 1099

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 4

ER -